Based on previous results showing that In1-ghrelin variant can promote features of aggressiveness in breast cancer [13] and pituitary tumor cells [16], and on the results of our study, which demonstrated that the expression of the In1-ghrelin variant is a valuable marker to classify patients according to prognosis, we further explored the functional role of In1-ghrelin in two NET cell models. This evidence concerns the gene GHRL and breast cancer.